Company: CERO
Filing Date: 2025-09-05
Form Type: 424B3
Source: 0001213900-25-085121
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-09-05
Form: 424B3
Chunk 4
---
, followed by an
expansion phase to evaluate safety and efficacy. Primary outcome measures include incidence of adverse events (AEs) and serious
adverse events (SAEs), incidence of dose limited toxicities and estimation of overall response rate (ORR), complete response (CR), composite
complete response (cCR), and measurable residual disease (MRD). Secondary outcome measures include pharmacokinetics (PK).

About CERo Therapeutics Holdings, Inc.

CERo is an innovative immunotherapy company advancing the development
of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables
it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed
to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected
to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy
cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated
activity of CER-T cells may offer advantages compared with currently approved CAR-T therapies and could potentially extend the reach of
cellular immunotherapy to both hematologic malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate
CER-1236 for hematological malignancies.

Forward-Looking Statements

This communication contains statements that are forward-looking and
as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and
the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking
statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical
or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“possible,” “potential,” “predict,” “project,” “should,” “strive,”
“would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that
a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking
statements. Such statements are based on the